Artemisinin Ameliorates Cognitive Decline in Diabetic Mice via NRF2-Mediated Ferroptosis Inhibition

Study Background and Research Question

Diabetes mellitus, particularly type 2 (T2DM), is associated with a high prevalence of cognitive impairment, with nearly half of T2DM patients experiencing learning and memory deficits. Despite this clinical burden, effective therapeutic strategies are lacking, largely owing to incomplete understanding of the underlying mechanisms. Recent advances have implicated ferroptosis—a form of regulated cell death driven by iron-dependent lipid peroxidation—as a contributor to neurodegeneration and diabetic complications. The nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor is a master regulator of antioxidant defenses and plays a pivotal role in cellular resistance to oxidative stress and ferroptosis. The central question addressed by Wang et al. (2024) is whether artemisinin, a well-known antimalarial with emerging neuroprotective properties, can mitigate cognitive decline in T2DM by modulating NRF2 activity and ferroptosis in the hippocampus.

Key Innovation from the Reference Study

The core innovation of this study lies in its mechanistic dissection of artemisinin's neuroprotective effect in a T2DM model. By employing the selective NRF2 inhibitor ML385 alongside a ferroptosis inducer (erastin), the authors establish causality between NRF2 activation, ferroptosis inhibition, and improved cognitive outcomes. This approach moves beyond correlative observations, positioning NRF2 signaling pathway inhibition (and its modulation) as a tractable axis for therapeutic intervention in diabetic cognitive dysfunction.

Methods and Experimental Design Insights

Wang et al. used a streptozotocin (STZ)-induced mouse model of T2DM, a well-validated platform for studying diabetes-related neurodegeneration. Mice were treated for four weeks with artemisinin (40 mg/kg, intraperitoneally), either alone or in combination with the NRF2 inhibitor ML385 or the ferroptosis inducer erastin. Cognitive performance was evaluated using the Morris water maze and Y maze tests, which are gold standards for spatial learning and memory assessment in rodents. Molecular and cellular endpoints included quantification of hippocampal reactive oxygen species (ROS), malondialdehyde (MDA), reduced glutathione (GSH), and ferrous iron (Fe²⁺) content, all central markers of oxidative stress and ferroptosis. Protein levels of NRF2, phosphorylated NRF2 (p-NRF2), heme oxygenase-1 (HO-1), and glutathione peroxidase 4 (GPX4) in the CA1 region of the hippocampus were measured by Western blotting. Histological assessment of neuronal damage and ultrastructural analysis of mitochondria were performed using H&E staining and transmission electron microscopy, respectively.

Protocol Parameters

• Artemisinin administration: 40 mg/kg, intraperitoneal injection, once daily for 4 weeks.
• NRF2 inhibition: ML385 co-administered as described in the study, dosage aligned with literature standards (for in vivo, typically 30 mg/kg, i.p., but verify for specific model requirements).
• Ferroptosis induction: Erastin used to provoke ferroptosis and validate pathway specificity.
• Behavioral assessment: Morris water maze and Y maze conducted after treatment period.
• Oxidative stress and ferroptosis markers: ROS, MDA, GSH, Fe²⁺ measured by commercial assay kits; Western blot analysis for NRF2, p-NRF2, HO-1, GPX4.
• Histology and ultrastructure: H&E staining for neuron injury; TEM for mitochondrial morphology.

Core Findings and Why They Matter

Treatment with artemisinin significantly reversed cognitive deficits in STZ-induced T2DM mice, as evidenced by improved performance in both the Morris water maze and Y maze. Artemisinin reduced hippocampal oxidative stress (lowered ROS and MDA), restored antioxidant capacity (elevated GSH), and decreased Fe²⁺ accumulation—key indicators of ferroptotic stress. At the molecular level, artemisinin upregulated p-NRF2, HO-1, and GPX4, supporting enhanced NRF2 pathway activity and ferroptosis suppression. Crucially, the neuroprotective effects of artemisinin were abolished when co-administered with ML385, confirming that NRF2 activation is a necessary mediator of artemisinin’s protective mechanism. Similarly, the pro-ferroptotic agent erastin counteracted artemisinin’s benefits, further substantiating the centrality of ferroptosis regulation. These findings delineate a causal chain: artemisinin activates NRF2, which upregulates antioxidant defenses and ferroptosis inhibitors, thereby preserving neuronal integrity and cognitive function in diabetic mice (Wang et al., 2024).

Comparison with Existing Internal Articles

The mechanistic insights provided by Wang et al. align with and extend prior work on NRF2 signaling pathway inhibition and its role in ferroptosis and therapeutic resistance. For instance, the internal article "Strategic NRF2 Inhibition: Mechanistic Insights and Translational Leverage" explores the application of selective NRF2 inhibitors, such as ML385, in oncology and redox biology. Both the reference paper and this internal resource emphasize the dual roles of NRF2 in cytoprotection and disease progression, but Wang et al. uniquely demonstrate the therapeutic potential of NRF2 modulation in the context of diabetic cognitive impairment. Other internal resources, such as "ML385: Selective NRF2 Inhibitor for Cancer & Redox Research" and "Harnessing Selective NRF2 Inhibition with ML385", detail the use of ML385 in models of cancer and liver disease. These articles corroborate the utility of ML385 for dissecting NRF2-dependent gene expression and oxidative stress modulation, but the Wang et al. study is among the first to systematically test the functional requirement of NRF2 in neuroprotection against diabetic pathology via ferroptosis regulation.

Limitations and Transferability

While the study provides robust evidence linking NRF2 activation to reduced ferroptosis and improved cognitive outcomes in a mouse model of T2DM, several limitations merit attention. The experimental design is limited to a single animal model, and the duration of treatment may not capture long-term effects or potential toxicity. Moreover, the translatability of artemisinin’s protective effects to human diabetic populations remains unproven. The use of ML385 as a pharmacological tool, while powerful, is subject to known constraints such as off-target effects and pharmacokinetic variability in vivo. Further studies in diverse models and eventual clinical translation are necessary to validate these findings.

Research Support Resources

Researchers aiming to investigate NRF2 signaling pathway inhibition, oxidative stress modulation, or ferroptosis in neurodegenerative or metabolic disease models can adopt methodologies similar to Wang et al. Notably, the selective NRF2 inhibitor ML385 (SKU B8300) is available from APExBIO for use in both in vitro and in vivo workflows, supporting the dissection of NRF2-dependent mechanisms in disease and therapeutic resistance. ML385 (CAS 846557-71-9) enables precise modulation of NRF2 activity and can be integrated into experimental designs to validate the specificity of NRF2-driven effects, as exemplified in the referenced study.